10.6084/M9.FIGSHARE.21434015
Yong Zhou
Yong
Zhou
Nanjing Drum Tower Hospital
Yuan Tan
Yuan
Tan
Simcere Pharmaceutical (China)
Qin Zhang
Qin
Zhang
Simcere Pharmaceutical (China)
Qianqian Duan
Qianqian
Duan
Simcere Pharmaceutical (China)
Jun Chen
Jun
Chen
Second Affiliated Hospital of Dalian Medical University
Additional file 2 of MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
Additional file 2: Fig. S2. The pan-cancer landscape of MED12 mutations across human tumors. The proportion of MED12 mutated tumors identified for each cancer type with alteration frequency in TCGA pan-cancer cohorts.
Immunology
figshare
2022
2022-10-31
2023-06-13
Figure
255947 Bytes
10.1177/1758835920937612
10.1177/1758835920937612
10.1056/NEJMcibr1214549
10.1056/NEJMcibr1214549
10.1186/s13045-017-0471-6
10.1186/s13045-017-0471-6
10.1158/1538-7445.AM2018-578
10.1158/1538-7445.AM2018-578
10.1016/j.cell.2012.10.035
10.1016/j.cell.2012.10.035
10.1038/s41423-020-0488-6
10.1038/s41423-020-0488-6
10.1016/j.tcb.2020.06.003
10.1016/j.tcb.2020.06.003
10.1038/s41591-018-0057-z
10.1038/s41591-018-0057-z
10.1038/s41577-019-0210-z
10.1038/s41577-019-0210-z
10.1016/j.ccell.2018.03.018
10.1016/j.ccell.2018.03.018
10.1126/science.aaa1348
10.1126/science.aaa1348
10.1038/s41588-018-0200-2
10.1038/s41588-018-0200-2
10.1126/science.aan5951
10.1126/science.aan5951
10.1126/science.aad0095
10.1038/s41591-019-0654-5
10.1038/s41591-019-0654-5
10.1038/s41588-018-0312-8
10.1038/s41588-018-0312-8
10.1186/s40001-022-00856-z
CC BY + CC0